Merck & Co. (MRK)
(Delayed Data from NYSE)
$116.60 USD
+0.05 (0.04%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $116.55 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.60 USD
+0.05 (0.04%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $116.55 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
by Zacks Equity Research
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
by Kinjel Shah
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
by Zacks Equity Research
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
by Zacks Equity Research
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.38% move from the prior day.
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
by Zacks Equity Research
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
by Zacks Equity Research
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.
Top Analyst Reports for Microsoft, Apple & Alphabet
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Apple Inc. (AAPL) and Alphabet Inc. (GOOGL), as well as a micro-cap stock CompX International Inc. (CIX).
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
by Zacks Equity Research
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Merck (MRK) Stock Moves 0.27%: What You Should Know
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $131.84, representing a +0.27% change from its previous close.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Merck (MRK) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.
Company News for June 4, 2024
by Zacks Equity Research
Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
by Kinjel Shah
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.